HIV- 1(MN) recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1(MN) recombinant glycoprotein 120 vaccine

AIDS Research and Human Retroviruses

Volumn 15, Issue 2, 1999, Pages 115-132

  Gorse, Geoffrey J ^a,m   Corey, Lawrence ^b   Patel, Gira B ^a   Mandava, Mahendra ^a   Hsieh, Ray Hahn ^c   Matthews, Thomas J ^d,l   Walker, Mary Clare ^e   Mcelrath, M Julie ^b   Berman, Phillip W ^f   Eibl, Martha M ^g   Belshe, Robert B ^a   Schwartz, David ^h   Harro, Clayton ^h   Clements Mann, Mary Lou ^h   Frey, Sharon E ^a   Kennedy, Donald J ^a   Mulligan, Mark ⁱ   Goepfert, Paul ⁱ   Mestecky, Jiri ⁱ   Jackson, Susan ⁱ   Hook, Edward ⁱ   Keefer, Michael C ^j   Dolin, Raphael ^j   Graham, Barney S ^k   Spearman, Paul ^k   Wright, Peter ^k   Weinhold, Kent ^l   Bolognesi, Dani ^l   Savarese, Barbara ^e   Grabowsky, Mark ^e   more..

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c EMMES CORPORATION   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f VaxGen Inc   (United States)

^g UNIVERSITY OF VIENNA   (Austria)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^k VANDERBILT UNIVERSITY   (United States)

^l DUKE UNIVERSITY   (United States)

^m S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN; HIV 1 IIIB GP120 SUBUNIT VACCINE; HIV-1 IIIB GP120 SUBUNIT VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; RECOMBINANT VACCINE; VAXSYN HIV 1 (GP160) VACCINE; VAXSYN HIV-1 (GP160) VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEADACHE; HELPER CELL; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; ADOLESCENT; BLOOD; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; SKIN TEST;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AIDS VACCINES; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNITY, ACTIVE; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MIDDLE AGED; SKIN TESTS; VACCINES, SYNTHETIC;

EID: 0033585452     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299311547     Document Type: Article

References (65)

1. Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Morgan BW, Atmar RL, Karzon DT, Bonnez W, Fernie BF, Montefiori DC, Stablein DM, Smith GE, Koff WC, and the NIAID AIDS Vaccine Clinical Trials Network: The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 1991;114:119-127.
2. Kovacs JA, Vasudevachari MB, Easter M, Davey RT, Falloon J, Polis MA, Metcalf JA, Salzman N, Baseler M, Smith GE, Volvovitz F, Masur H, and Lane HC: Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV seronegative volunteers by immunization with recombinant gp160. J Clin Invest 1993;92:919-928.
3. Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML, Gorse GJ, Wright PF, Matthews TJ, Smith GE, Lawrence D, Dolin R, and the AIDS Vaccine Clinical Trials Network: Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res Hum Retroviruses 1994;10:1713-1723.
4. Belshe RB, Clements ML, Dolin R, Graham BS, McElrath J, Gorse GJ, Schwartz D, Keefer MC, Wright P, Corey L, Bolognesi DP, Matthews TJ, Stablein DM, O'Brien FS, Eibl M, Dorner F, Koff W, and the National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network: Safety and immunogenicity of a fully glycosytated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993;168:1387-1395.
5. Gorse GJ, Schwartz DH, Graham BS, Matthews TJ, Stablein DM, Frey SE, Belshe RB, Clements ML, Wright PF, Eibl M, Fast PE, and the NIAID AIDS Vaccine Clinical Trials Network: HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immunol 1994;98:178-184.
6. IIIB rgp120 subunit vaccine. Lancet 1993;342:69-73.
7. Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE, and the NLAID AIDS Vaccine Evaluation Group: Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adult volunteers: Recombinant envelope glycoprotein gp120. Ann Intern Med 1996;125:270-279:
8. McElrath MJ, Corey L, Clements ML, Belshe R, Dolin R, Graham B, Fast P, Matthews T, Francis D, Duliege AM, and the NIAID AIDS Vaccine Trials Network: A phase II HIV prophylactic vaccine trial in seronegative volunteers: Expanded safety and immunogenicity evaluation of two recombinant gp120 vaccines. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida. American Society for Microbiology, Washington, DC, 1994, p. 238. [Abstract 1241]
9. Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, Stablein DM, Twaddell T, Berman PW, Gregory T, Izu AE, Walker MC, and Fast PE, for the NIAID AIDS Vaccine Clinical Trials Network: Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-480.
10. SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 1994;170: 1288-1291.
11. Cooney EL, McElrath MJ, Corey L, Hu S-L, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, and Greenberg PD: Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993;90: 1882-1886.
12. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, Corey L, Stablein DM, Esterlitz JR, Hu S-L, Smith GE, Fast PE, Koff WC, and the NIAID AIDS Vaccine Clinical Trials Network: Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993; 167:533-537.
13. Walker MC and Fast PE: Clinical trials of candidate AIDS vaccines. AIDS 1994;8(S1):S213-S236.
14. MN recombinant gp160 vaccine by dose and schedule of administration. Vaccine 1998;16:493-506.
15. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, and Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 1990;345:622-625.
16. Fultz PN, Nara P, Barré-Sinoussi F, Chaput A, Greenberg ML, Muchmore E, Kieny M-P, and Girard M: Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992;256:1687-1690.
17. Barrett N, Eder G, and Dorner F: Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees. Biotechnol Ther 1990;2:91-106.
18. Girard M, Meignier B, Barré-Sinoussi F, Kieny M-P, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K, and Fultz PN: Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol 1995;69:6239-6248.
19. Berman PW, Murthy KK, Wrin T, Vennari JC, Cobb EK, Eastman DJ, Champe M, Nakamura GR, Davison D, Powell MF, Bussiere J, Francis DP, Matthews T, Gregory TJ, and Obijeski JF: Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 1996;173:52-59.
20. SF2. AIDS 1995;9: 1313-1322.
21. Gorse GJ, Patel GB, Newman FK, Mandava M, and Belshe RB for the NIAID AIDS Vaccine Clinical Trials Network: Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. Vaccine 1995;13:1170-1179.
22. Gorse GJ, Belshe RB, Newman FK, Frey SE, and the NIAID AIDS Vaccine Clinical Trials Network: Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160. Vaccine 1992;10:383-388.
23. Keefer MC, Bonnez W, Roberts NJ Jr, Dolin R, and Reichman RC: Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis 1991;163: 448-453.
24. Takahashi H, Nakagawa Y, Pendleton CD, Houghton RA, Yokomuro K, Germain RN, and Berzovsky JA: Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science 1992;255:333-336.
25. Stanhope PE, Clements ML, and Siliciano RF: Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J Infect Dis 1993;168:92-100.
26. Hammond SA, Bollinger RC, Stanhope PE, Quinn TC, Schwartz D, Clements ML, and Siliciano RF: Comparative clonal analysis of human immunodeficiency virus type 1 (HTV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992; 176:1531-1542.
27. Stanhope RE, Liu AY, Pavlat W, Pitha PM, Clements ML, and Siliciano RF: An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J Immunol 1993;150:4672-4686.
28. Orentas RJ, Hildreth JEK, Obah E, Polydefkis M, Smith GE, Clements ML, and Siliciano RF: Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990;248:1234-1237.
29. El-Daher N, Keefer MC, Reichman RC, Dolin R, and Roberts NJ Jr: Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J Infect Dis 1993;168: 306-313.
30. Gorse GJ, Yang EY, Belshe RB, and Berman PW for the NIAID AIDS Vaccine Evaluation Group: Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. Clin Diag Lab Immunol 1996;3:769-773.
31. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS, for the National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
32. Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, Clements ML, Duliege A-M, Excler J-L, Hioe C, Kahn J, McElrath MJ, Sharpe S, Sinangil F, Steimer K, Walker MC, Wassef N, and Xu S: Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J Infect Dis 1997;175:764-774.
33. Belshe RB, Clements ML, Keefer MC, Graham BS, Corey L, Sposto R, Wescott S, Lawrence D, and the NIAID AIDS Vaccine Clinical Trials Group: Interpreting HIV serodiagnostic test results in the 1990s: Social risk of HIV vaccine studies in uninfected volunteers. Ann Intern Med 1994;121:584-589.
34. Barrett N, Mitterer A, Mundt W, Eibl J, Eibl M, Gallo RC, Moss B, and Dorner F: Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS Res Hum Retroviruses 1989;5:159-171.
35. Berman PW, Matthews TJ, Riddle L, Champe M, Hobbs MR, Nakamura GR, Mercer J, Eastman DJ, Lucas C, Langlois AJ, Wurm FM, and Gregory TJ: Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J Virol 1992;66:4464-4469.
36. Gorse G, Rogers J, Perry JE, Newman F, Frey S, Patel G, Belshe R, and the NIAID AIDS Vaccine Clinical Trials Network: HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. Vaccine 1995;13:209-214.
37. Gorse GJ, Frey SE, Newman FK, Belshe RB, and the NIAID AIDS Vaccine Clinical Trials Network: Detection of binding antibodies to native and recombinant HIV-1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. J Clin Microbiol 1992;30:2606-2612.
38. Skinner MA, Langlois AJ, McDanal CB, McDougal JS, Bolognesi DP, and Matthews TJ: Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol 1988;62:4195-4200.
39. Montefiori DC, Robinson WE Jr, Schuffman SS, and Mitchell WM: Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 1988;26:231-235.
40. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, and Montefiori DC: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long term non-progressive infection. J Infect Dis 1997;176:924-932.
41. Gorse G, Frey SE, Patel G, Newman FK, Belshe RB, and the NIAID AIDS Vaccine Clinical Trials Network: Vaccine induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. Vaccine 1994;12:912-918.
42. Gorse GJ, Patel GB, Newman FK, Belshe RB, Berman PW, Gregory TJ, and Matthews TJ, for the NIAID AIDS Vaccine Evaluation Group: Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. Clin Diag Lab Immunol 1996;3:378-386.
43. Mann DL, O'Brien SJ, Gilbert DA, Reid Y, Popovic M, Read-Connole E, and Gallo RC: Origin of the HIV-susceptible human CD4+ cell line H9. AIDS Res Hum Retroviruses 1989;5:253-255.
44. Popovic M, Read-Connole E, and Gallo RC: T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet 1984;2:1472-1473.
45. Popovic M, Samgadharan MG, Read E, and Gallo RC: Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497-500.
46. Gallo RC, Salahuddin SZ, Popovic M, Schearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, White G, Foster P, and Markham PD: Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk of AIDS. Science 1984;224:500-503.
47. Shaw GM, Hahn BH, Arya SK, Groopman JE, Gallo RC, and Wong-Staal F: Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 1984;226:1165-1170.
48. Sanchez-Pescador R, Power MD, Barr PJ, Steimer KS, Stempien MM, Brown-Shimer SL, Gee WW, Renard A, Randolph A, Levy JA, Dina D, and Luciev PA: Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 1985;227: 484-492.
49. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, and Oshiro LS: Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984;225:840-842.
50. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968;21(Suppl. 97):77-89.
51. Gorse GJ and Belshe RB: Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses. Scand J Infect Dis 1991;23:7-17.
52. Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE, the AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group: Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. J Infect Dis 1998;177:310-319.
53. Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G and the AIDS Vaccine Evaluation Group: Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis 1998;177:301-309.
54. SF-2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998;177:1230-1246.
55. Evans TG, Keefer MC, Wolff M, Weinhold K, Exeler J-L, Duliege A-M, Fast P, McElrath MJ, Graham BS, Clements-Mann ML, Mulligan M, Gorse GJ, and the NIAID AIDS Vaccine Evaluation Group: A canarypox recombinant containing HIV-1 env, gag, pol, and nef genes (vCP300) given with SF-2 rgp120 elicits broad, durable CD8+ CTL in seronegative volunteers. In: 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, American Society for Microbiology, Washington, DC, 1998. [Abstract 533]
56. Scott MG, Briles DE, and Nahm MH: Selective IgG subclass expression: Biologic, clinical and functional aspects. In: The Human IgG subclasses: Molecular Analysis of Structure, Function and Regulation (Shakib F, ed.). Pergamon Press, Oxford, 1990, pp. 161-183.
57. Jefferis R: Structure-function relationships of IgG subclasses. In: The Human IgG Subclasses: Molecular Analysis of Structure, Function and Regulation (Shakib F, ed.). Pergamon Press, Oxford, 1990, pp. 93-108.
58. Anderson CL and Looney RJ: Human leukocyte IgG Fe receptors. Immunol Today 1986;7:264-266.
59. Lawrence DA, Weigle WO, and Spiegelberg HL: Immunoglobulins cytophilic for human lymphocytes, monocytes and neutrophils. J Clin Invest 1975;55:368-376.
60. Kovacsovics-Bankowski M, Carini C, Kashala O, and Essex M: Isotypic distribution of HIV-1-specific antibodies in individuals from Central Africa. Viral Immunol 1992;5:243-248.
61. Broliden PA, Morfeldt-Mansson L, Rosen J, Jondal M, and Wahren B: Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients. Clin Exp Immunol 1989;76:216-221.
62. Khalife J, Guy B, Capron M, Kieny M-P, Ameisen J-C, Montagnier L, Lecocq J-P, and Capron A: Isotypic restriction of the antibody response to human immunodeficiency virus. AIDS Res Hum Retroviruses 1988;4:3-9.
63. Skvaril F: IgG subclasses in viral infections. Monogr Allergy 1986;19:134-143.
64. Hammarström L and Smith CIE: Subclass restrictions of IgG antibody responses. In: The Human IgG Subclasses: Molecular Analysis of Structure, Function and Regulation. Pergamon Press, Oxford, 1990, pp. 301-312.
65. Mathiesen T, Persson M, Sudqvist V, and Wahren B: Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separate IgG subclasses 1, 3 and 4 against herpes simplex virus. Clin Exp Immunol 1988;72:211-215.